Journal of Clinical Investigation · 2010 · 83 citations · 45 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCytokine-based TherapyCytokines In Tumor ImmunityCytotoxic T Lymphocyte ResponsesT Cell Responses To TumorsAdaptive Antitumor ImmunityAdoptive ImmunotherapyCd8 Positive T CellsCd8 T Cell ActivationEffector Lymphocyte ActivationLymphocyte Activation ThresholdsT Cell Activation ModulationTumor-specific T Cell Clones
The clinical use of adoptive immunotherapy with tumor-reactive T cells to treat established cancers is limited in part by the poor in vivo survival and function of the transferred T cells. Although administration of exogenous cytokines such as IL-2 can promote T cell survival, such strategies have many nonspecific activities and are often associated with toxicity. We show here that abrogating expression of Casitas B-lineage lymphoma b (Cbl-b), a negative regulator of lymphocyte activation, in tumor-reactive CD8(+) T cells expanded ex vivo increased the efficacy of adoptive immunotherapy of disseminated leukemia in mice. Mechanistically, Cbl-b abrogation bypassed the requirement for exogenous IL-2 administration for tumor eradication in vivo. In addition, CD8(+) T cells lacking Cbl-b demonstrated a lower threshold for activation, better survival following target recognition and stimulation, and enhanced proliferative responses as a result of both IL-2-dependent and -independent pathways. Importantly, siRNA knockdown of Cbl-b in human CD8(+)CD28- effector T cell clones similarly restored IL-2 production and proliferation following target recognition independent of exogenous IL-2, enhanced IFN-γ production, and increased target avidity. Thus, abrogating Cbl-b expression in effector T cells may improve the efficacy of adoptive therapy of some human malignancies.
45
Cassian Yee, John A. Thompson, D. Byrd et al. · Proceedings of the National Academy of Sciences · 2002 · 1.2K citations
Medicine, Immunology, Oncology +17
Cbl-b regulates the CD28 dependence of T-cell activation
Yungping J. Chiang, Hemanta K. Kole, Karen Brown et al. · Nature · 2000 · 638 citations